Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Chemotherapy-induced loss of bone and muscle mass in a mouse model of breast cancer bone metastases and cachexia.

Hain BA, Xu H, Wilcox JR, Mutua D, Waning DL.

JCSM Rapid Commun. 2019 Jan-Jun;2(1). pii: e00075.

2.

Chronic Treatment with Multi-Kinase Inhibitors Causes Differential Toxicities on Skeletal and Cardiac Muscles.

Huot JR, Essex AL, Gutierrez M, Barreto R, Wang M, Waning DL, Plotkin LI, Bonetto A.

Cancers (Basel). 2019 Apr 23;11(4). pii: E571. doi: 10.3390/cancers11040571.

3.

Cancer- and Chemotherapy-Induced Musculoskeletal Degradation.

Sturgeon KM, Mathis KM, Rogers CJ, Schmitz KH, Waning DL.

JBMR Plus. 2019 Feb 25;3(3):e10187. doi: 10.1002/jbm4.10187. eCollection 2019 Mar. Review.

4.

A "Connexin" Responsible for the Fatal Attraction of Cancer to Bone.

Waning DL, Guise TA, Mohammad KS.

Cell Metab. 2019 Jan 8;29(1):6-8. doi: 10.1016/j.cmet.2018.12.014.

5.

Osteolytic Breast Cancer Causes Skeletal Muscle Weakness in an Immunocompetent Syngeneic Mouse Model.

Regan JN, Mikesell C, Reiken S, Xu H, Marks AR, Mohammad KS, Guise TA, Waning DL.

Front Endocrinol (Lausanne). 2017 Dec 19;8:358. doi: 10.3389/fendo.2017.00358. eCollection 2017.

6.

Bone-Induced Expression of Integrin β3 Enables Targeted Nanotherapy of Breast Cancer Metastases.

Ross MH, Esser AK, Fox GC, Schmieder AH, Yang X, Hu G, Pan D, Su X, Xu Y, Novack DV, Walsh T, Colditz GA, Lukaszewicz GH, Cordell E, Novack J, Fitzpatrick JAJ, Waning DL, Mohammad KS, Guise TA, Lanza GM, Weilbaecher KN.

Cancer Res. 2017 Nov 15;77(22):6299-6312. doi: 10.1158/0008-5472.CAN-17-1225. Epub 2017 Aug 30.

7.

The Role of TGFβ in Bone-Muscle Crosstalk.

Regan JN, Trivedi T, Guise TA, Waning DL.

Curr Osteoporos Rep. 2017 Feb;15(1):18-23. doi: 10.1007/s11914-017-0344-5. Review.

8.

Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo.

Wright LE, Harhash AA, Kozlow WM, Waning DL, Regan JN, She Y, John SK, Murthy S, Niewolna M, Marks AR, Mohammad KS, Guise TA.

Oncotarget. 2017 Jan 31;8(5):8406-8419. doi: 10.18632/oncotarget.14139.

9.

Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs.

Barreto R, Waning DL, Gao H, Liu Y, Zimmers TA, Bonetto A.

Oncotarget. 2016 Jul 12;7(28):43442-43460. doi: 10.18632/oncotarget.9779.

10.

Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.

Wang H, Cai S, Bailey BJ, Reza Saadatzadeh M, Ding J, Tonsing-Carter E, Georgiadis TM, Zachary Gunter T, Long EC, Minto RE, Gordon KR, Sen SE, Cai W, Eitel JA, Waning DL, Bringman LR, Wells CD, Murray ME, Sarkaria JN, Gelbert LM, Jones DR, Cohen-Gadol AA, Mayo LD, Shannon HE, Pollok KE.

J Neurosurg. 2017 Feb;126(2):446-459. doi: 10.3171/2016.1.JNS152513. Epub 2016 May 13.

11.

Skeletal muscle Ca(2+) mishandling: Another effect of bone-to-muscle signaling.

Regan JN, Waning DL, Guise TA.

Semin Cell Dev Biol. 2016 Jan;49:24-9. doi: 10.1016/j.semcdb.2015.11.007. Epub 2015 Nov 24. Review.

12.

Excess TGF-β mediates muscle weakness associated with bone metastases in mice.

Waning DL, Mohammad KS, Reiken S, Xie W, Andersson DC, John S, Chiechi A, Wright LE, Umanskaya A, Niewolna M, Trivedi T, Charkhzarrin S, Khatiwada P, Wronska A, Haynes A, Benassi MS, Witzmann FA, Zhen G, Wang X, Cao X, Roodman GD, Marks AR, Guise TA.

Nat Med. 2015 Nov;21(11):1262-1271. doi: 10.1038/nm.3961. Epub 2015 Oct 12.

13.

Assessment of muscle mass and strength in mice.

Bonetto A, Andersson DC, Waning DL.

Bonekey Rep. 2015 Aug 19;4:732. doi: 10.1038/bonekey.2015.101. eCollection 2015.

14.

TGFβ-Mediated induction of SphK1 as a potential determinant in human MDA-MB-231 breast cancer cell bone metastasis.

Stayrook KR, Mack JK, Cerabona D, Edwards DF, Bui HH, Niewolna M, Fournier PG, Mohammad KS, Waning DL, Guise TA.

Bonekey Rep. 2015 Jul 8;4:719. doi: 10.1038/bonekey.2015.88. eCollection 2015.

15.

Cancer-associated muscle weakness: What's bone got to do with it?

Waning DL, Guise TA.

Bonekey Rep. 2015 May 20;4:691. doi: 10.1038/bonekey.2015.59. eCollection 2015. Review.

16.

Signaling pathways involved in megakaryocyte-mediated proliferation of osteoblast lineage cells.

Cheng YH, Streicher DA, Waning DL, Chitteti BR, Gerard-O'Riley R, Horowitz MC, Bidwell JP, Pavalko FM, Srour EF, Mayo LD, Kacena MA.

J Cell Physiol. 2015 Mar;230(3):578-86. doi: 10.1002/jcp.24774.

17.

Molecular mechanisms of bone metastasis and associated muscle weakness.

Waning DL, Guise TA.

Clin Cancer Res. 2014 Jun 15;20(12):3071-7. doi: 10.1158/1078-0432.CCR-13-1590. Epub 2014 Mar 27. Review.

18.

Role of TGF-β in breast cancer bone metastases.

Chiechi A, Waning DL, Stayrook KR, Buijs JT, Guise TA, Mohammad KS.

Adv Biosci Biotechnol. 2013 Oct 1;4(10C):15-30.

19.

Cancer-associated osteoclast differentiation takes a good look in the miR(NA)ror.

Waning DL, Mohammad KS, Guise TA.

Cancer Cell. 2013 Oct 14;24(4):407-9. doi: 10.1016/j.ccr.2013.10.001.

20.

Pyk2 regulates megakaryocyte-induced increases in osteoblast number and bone formation.

Cheng YH, Hooker RA, Nguyen K, Gerard-O'Riley R, Waning DL, Chitteti BR, Meijome TE, Chua HL, Plett AP, Orschell CM, Srour EF, Mayo LD, Pavalko FM, Bruzzaniti A, Kacena MA.

J Bone Miner Res. 2013 Jun;28(6):1434-45. doi: 10.1002/jbmr.1876.

21.

Induction of apoptotic genes by a p73-phosphatase and tensin homolog (p73-PTEN) protein complex in response to genotoxic stress.

Lehman JA, Waning DL, Batuello CN, Cipriano R, Kadakia MP, Mayo LD.

J Biol Chem. 2011 Oct 21;286(42):36631-40. doi: 10.1074/jbc.M110.217620. Epub 2011 Aug 26.

22.

c-Abl phosphorylation of Mdm2 facilitates Mdm2-Mdmx complex formation.

Waning DL, Lehman JA, Batuello CN, Mayo LD.

J Biol Chem. 2011 Jan 7;286(1):216-22. doi: 10.1074/jbc.M110.183012. Epub 2010 Nov 16.

23.

Controlling the Mdm2-Mdmx-p53 Circuit.

Waning DL, Lehman JA, Batuello CN, Mayo LD.

Pharmaceuticals (Basel). 2010 May 18;3(5):1576-1593.

24.

Cul4A is required for hematopoietic cell viability and its deficiency leads to apoptosis.

Waning DL, Li B, Jia N, Naaldijk Y, Goebel WS, HogenEsch H, Chun KT.

Blood. 2008 Jul 15;112(2):320-9. doi: 10.1182/blood-2007-11-126300. Epub 2008 Mar 13.

25.

Cul4A is required for hematopoietic stem-cell engraftment and self-renewal.

Li B, Jia N, Waning DL, Yang FC, Haneline LS, Chun KT.

Blood. 2007 Oct 1;110(7):2704-7. Epub 2007 Jul 6.

26.

Activation of a paramyxovirus fusion protein is modulated by inside-out signaling from the cytoplasmic tail.

Waning DL, Russell CJ, Jardetzky TS, Lamb RA.

Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9217-22. Epub 2004 Jun 14.

27.
28.

Requirements for budding of paramyxovirus simian virus 5 virus-like particles.

Schmitt AP, Leser GP, Waning DL, Lamb RA.

J Virol. 2002 Apr;76(8):3952-64.

Supplemental Content

Loading ...
Support Center